Hepatocellular carcinoma tumor cells and associated tumor microenvironment (HCC TME) (HCC TME)

Hepatocellular carcinoma (HCC) tumor cells and the associated tumor microenvironment (TME) represent a complex biological system rather than a single molecular target. The HCC TME is characterized by a dense stroma containing cancer-associated fibroblasts, endothelial cells, and a diverse array of immune cells such as tumor-associated macrophages and regulatory T cells (NIH, 2023). This environment is typically immunosuppressive and highly angiogenic, facilitating tumor growth, invasion, and resistance to therapy (PubMed: 32853550). Current therapeutic approaches target various components within this milieu, including the use of multi-kinase inhibitors like sorafenib and lenvatinib to inhibit angiogenesis and cell proliferation, and immune checkpoint inhibitors like atezolizumab to counteract immune evasion (Nature Reviews Clinical Oncology, 2021). Because the TME is dynamic and heterogeneous, it presents significant challenges for treatment, often requiring combination therapies to achieve clinical efficacy. This systemic "target" is central to understanding HCC pathogenesis and the development of next-generation precision medicines (Journal of Hepatology, 2019).

Other names

HCC tumor microenvironmentLiver cancer microenvironmentHepatocellular carcinoma nicheHCC TME

Multi-kinase inhibition (targeting VEGFR, PDGFR, FGFR), VEGF neutralization, and immune checkpoint inhibition (PD-1/PD-L1 and CTLA-4 blockade).